<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384733</url>
  </required_header>
  <id_info>
    <org_study_id>The Skagen Trial 1</org_study_id>
    <nct_id>NCT02384733</nct_id>
  </id_info>
  <brief_title>Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost</brief_title>
  <official_title>The Skagen Trial 1, Moderately Hypofractionated Loco-regional Adjuvant Radiation Therapy of Early Breast Cancer Combined With a Simultaneous Integrated Boost: a Randomised Clinically Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Breast Cancer Cooperative Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the difference in late radiation morbidity between
      hypofractionated and normofractionated loco-regional breast irradiation irrespective of
      mastectomy or lumpectomy. In patients who a candidates for a boost, the boost will be
      provided as a simultaneous integrated boost.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The randomization is between 50 Gy / 25 fractions and 40 Gy/15 fractions, 5 fractions weekly.
      In patients treated with boost 2 dose levels are accepted: 16 Gy/8 fractions and 10 Gy/5
      fractions. These boost treatments will be provided as simultaneous integrated boost, where
      the overall treatment time in general is shortened 5 days. Thus the dose levels for boost
      patients are:

      63 Gy / 51.52 Gy / 28 fractions, 57 Gy / 50 Gy / 25 fractions, 52.2 Gy / 42.3 Gy / 18
      fractions, and 45.75 Gy / 40 Gy / 15 fractions.

      The primary endpoint is arm lymphedema 3 years after radiation therapy, but other late
      radiation morbidities will also be evaluated along with recurrence and sites of recurrence.
      Follow up of morbidity will continue for 10 years.

      The hypothesis is that women operated for early breast cancer with indication for
      loco-regional radiation therapy can be offered moderately hypofractionated therapy without
      developing more late radiation induced morbidity compared to normofractionated radiation
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2036</completion_date>
  <primary_completion_date type="Anticipated">March 2036</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of ipsilateral arm lymphedema</measure>
    <time_frame>3 years</time_frame>
    <description>&gt;=10% increased arm circumference compared to the other arm defines edema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibrosis grade 2-3</measure>
    <time_frame>3 years</time_frame>
    <description>Breast or chest wall induration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm range of motion</measure>
    <time_frame>3 years</time_frame>
    <description>Impaired shoulder movement is present when &gt;20 degrees difference between arms at flexion and/or abduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of dyspigmentation</measure>
    <time_frame>3 years</time_frame>
    <description>Grade 2 or worse dyspigmentation compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>10 years</time_frame>
    <description>Any recurrence location and time to event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of pain in the irradiated area</measure>
    <time_frame>3 years</time_frame>
    <description>Pain in the irradiated area measured on visual analog scale compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sensibility</measure>
    <time_frame>3 years</time_frame>
    <description>Change in sensibility in the irradiated area compared to baseline measured as yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of edema on breast / chest wall</measure>
    <time_frame>3 years</time_frame>
    <description>Grade 2 or worse edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of telangiectasia in irradiated area</measure>
    <time_frame>3 years</time_frame>
    <description>Grade 2 or worse telangiectasia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Lymphedema</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Hypofractionated loco-regional RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normofractionated loco-regional RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Loco-regional RT</intervention_name>
    <arm_group_label>Hypofractionated loco-regional RT</arm_group_label>
    <arm_group_label>Normofractionated loco-regional RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Operated for early node-positive breast cancer with indication for loco-regional breast
        radiotherapy

        Exclusion Criteria:

        Previous radiotherapy to chest wall, pregnant/lactating, comorbidity which may hinder 10
        years follow up
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Stenbygaard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aalborg Universitetshospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Jakobsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mette Nielsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Birgitte Offersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanne Nielsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claus Kamby, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zahra Taheri-Kadkhoda, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Naestved Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mechthild Krause, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Technische Universität Dresden Klinik und Poliklinik für Strahlentherapie und Radioonkologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Schreiber, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Praxis für Strahlentherapie, Dresden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingvil Mjaaland, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stavanger Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Verity Ahern, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New South Wales Breast Cancer Institute, Westmead Hospital, Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanja Marinko, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Oncology Ljubljana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carine Kirkove, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radiotherapy Department Université Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Egil Blix, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of North Norway, Tromsoe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Unn-Miriam Kasti</last_name>
    <role>Study Chair</role>
    <affiliation>Kristiansand Hospital, Norway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birgitte V. Offersen, MD, Ph.D</last_name>
    <phone>+45 7846 2547</phone>
    <email>birgoffe@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanne M. Nielsen, MD, Ph.D</last_name>
    <phone>+45 7846 2547</phone>
    <email>haniesen@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgitte Offersen, MD</last_name>
      <email>birgoffe@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Hanne Nielsen, MD</last_name>
      <email>hanisen@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Breast Cancer Cooperative Group</investigator_affiliation>
    <investigator_full_name>Birgitte Offersen</investigator_full_name>
    <investigator_title>MD, professor, ph.d.</investigator_title>
  </responsible_party>
  <keyword>Radiation induced morbidity, recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

